1. Hematologic effects of linezolid: summary of clinical experience.
- Author
-
Gerson SL, Kaplan SL, Bruss JB, Le V, Arellano FM, Hafkin B, and Kuter DJ
- Subjects
- Blood Cell Count, Clinical Trials as Topic, Hemoglobins metabolism, Humans, Linezolid, Neutropenia blood, Neutropenia chemically induced, Retrospective Studies, Thrombocytopenia blood, Thrombocytopenia chemically induced, Acetamides adverse effects, Anemia blood, Anemia chemically induced, Anti-Infective Agents adverse effects, Oxazolidinones adverse effects
- Abstract
Linezolid has been associated with reversible myelosuppression. Clinical trial data were evaluated for anemia, thrombocytopenia, and neutropenia. Thrombocytopenia and a slight increased risk for anemia were evident at > or =2 weeks of linezolid treatment. Hematologic abnormalities were consistent with mild, reversible, duration-dependent myelosuppression. Appropriate monitoring is warranted with linezolid use.
- Published
- 2002
- Full Text
- View/download PDF